학술논문
Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial
Document Type
Article
Author
Moyle, Graeme; Assoumou, Lambert; de Castro, Nathalie; Post, Frank A; Curran, Adrian; Rusconi, Stefano; De Wit, Stephane; Stephan, Christoph; Raffi, François; Johnson, Margaret; Masia, Mar; Vera, Jaime; Jones, Bryn; Grove, Richard; Fletcher, Carl; Duffy, Annie; Morris, Kellie; Pozniak, Anton; Moyle, Graeme; de Castro, Nathalie; Post, Frank; Curran, Adrian; Rusconi, Stefano; De Wit, Stephane; Stephan, Christoph; Raffi, François; Johnson, Margaret; Masia, Mar; Vera, Jaime; Winston, Alan; Kegg, Stephen; Waters, Laura; Orkin, Chole; Ustianowski, Andrew; Reeves, Iain; Leen, Clifford; Perry, Meghan; Portilla, Joaquin; Blanco, Jose Luis; Montejaro, Rocio; Domingo, Pere; Molina, Jean Michel; Katlama, Christine; Morlat, Philippe; Kenyon, Christopher; Puoti, Massimo; Rizzardini, Giuliano; Castagna, Antonella; Castelli, Francesco; Giacomelli, Andrea; Rockstroh, Jürgen; Esser, Stefan; Hoffmann, Christian; Mallon, Patrick
Source
The Lancet HIV; March 2024, Vol. 11 Issue: 3 pe156-e166, 11p
Subject
Language
ISSN
24054704; 23523018
Abstract
The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to maintain viral suppression with dolutegravir plus rilpivirine in people with Lys103Asn mutations whose HIV was previously managed with other treatment regimens.